© 2020 MJH Life Sciences™ and Cancer Network. All rights reserved.
Thomas J. Polascik, MD | Authors
Articles
Low-Risk and Very-Low-Risk Prostate Cancer: Is There a Role for Focal Therapy in the Era of Active Surveillance? Yes, the Two Approaches Complement Each Other
November 15, 2014
Investigators and physicians caring for the spectrum of prostate cancer should have a targeted treatment option available for patients who would benefit by it.